Figure 2: Outlook towards anti-VEGF biosimilars. Bulk of the respondents in the VIBE surveys were aware regarding biosimilars (a) and feel that they require more stringent procedure for approval (b). From 2018 to 2020, there was a rise in proportion of respondents using ranibizumab biosimilar, while simultaneously, the usage of bevacizumab biosimilars declined (c). Similar trend was also noted when the respondents favored use ranibizumab biosimilar (d)